CytoMed Therapeutics (GDTC) Notes Payables (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Notes Payables for 5 consecutive years, with $31516.6 as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 11.35% to $31516.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31516.6 through Dec 2025, up 11.35% year-over-year, with the annual reading at $31765.0 for FY2025, 15.27% up from the prior year.
  • Notes Payables hit $31516.6 in Q4 2025 for CytoMed Therapeutics, up from $28304.4 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $284211.5 in Q4 2021 to a low of $25128.7 in Q4 2023.
  • Historically, Notes Payables has averaged $122078.0 across 5 years, with a median of $31516.6 in 2025.
  • Biggest five-year swings in Notes Payables: plummeted 89.58% in 2023 and later grew 12.64% in 2024.
  • Year by year, Notes Payables stood at $284211.5 in 2021, then dropped by 15.12% to $241229.0 in 2022, then tumbled by 89.58% to $25128.7 in 2023, then increased by 12.64% to $28304.4 in 2024, then grew by 11.35% to $31516.6 in 2025.
  • Business Quant data shows Notes Payables for GDTC at $31516.6 in Q4 2025, $28304.4 in Q4 2024, and $25128.7 in Q4 2023.